Program
Please note that this meeting will take place as an in-person event in Boston and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.
CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
*-Short talk from proffered abstract
Friday, october 18
saturday, october 19
- Plenary Session 1: Good and Bad CD4 T-cell Help
- Plenary Session 2: Mass Spectrometry / MHC
- Plenary Session 3: T-cell Engineering / Cellular Therapy
sunday, october 20
- Plenary Session 4: Immune Checkpoint Expression Profiles and Therapeutic Combinations
- Plenary Session 5: Vaccines
- Plenary Session 6: Emerging Technologies, Microbiome, and Immunometabolism
- Keynote Lecture
monday, october 21
Welcome and Opening Keynote
6:30-7:30 p.m.
- Susan M. Kaech, Salk Institute for Biological Studies, La Jolla, California
OPENING RECEPTION
7:30-9:30 p.m.
CONTINENTAL BREAKFAST
7-8 A.M.
Plenary Session 1: Good and Bad CD4 T cell Help
8-10:05 a.m.
Session Chair: Sergio Quezada, University College London (UCL) Cancer Institute, London, England
- Cancer biomarker defining the subset of HPV16+ head and neck cancer patients benefiting from therapeutic vaccine combination with anti-PD-1
Cornelius JM Melief, ISA Pharmaceuticals, Oegstgeest, Netherlands - Treg targeting at the interface of adaptive and innate immunity-targetable bad help
Sergio Quezada - Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, Missouri
BREAK
10:05-10:25 A.M.
Plenary Session 2: Mass Spectrometry / MHC
10:25-12:30 p.m.
Session Chair: To be announced
- Using FAIMS to improve detection of tumor neoantigens
Cheryl Lichti, Washington University School of Medicine in St. Louis, St. Louis, Missouri - Insight into PTM-driven antigenicity
Yifat Merbl, Wiezmann Institute of Science, Rehovat, Israel - Immunopeptidomic-driven exploration of the tumor antigenic landscape
Michal Bassani Sternberg, University of Lausanne, Lausanne, Switzerland
Lunch Break (on your own)
12:30-2:30 p.m.
Plenary Session 3: T-cell Engineering / Cellular Therapy
2:30-4:35 p.m.
Session Chair: Yvonne Y. Chen, University of California, Los Angeles, California
- Yvonne Y. Chen
- Fourth generation CAR-Tregs
Megan Levings, BC Children’s Hospital Research Institute, Vancouver, BC, Canada
Additional speaker to be announced
Poster Session A
4:45-7 p.m.
CONTINENTAL BREAKFAST
7-8 A.M.
Plenary Session 4: New Checkpoints and Combinations
8-10:05 a.m.
Session Chair: Fernando Vidal-Vanaclocha, The George Washington University, Washington, DC
- Distinct immune checkpoint gene signatures of breast cancer subtypes with and without HER2-regulated stromal cell genes
Fernando Vidal-Vanaclocha
Additional speakers to be announced
BREAK
10:05-10:25 A.M.
Plenary Session 5: Vaccines
10:25 a.m.-12:30 p.m.
Session Chair: Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, Missouri
- Jeffrey S. Weber, NYU Langone Health, New York, New York
- Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
- Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York
LUNCH BREAK (ON YOUR OWN)
12:30-2:30 P.M.
Plenary Session 6: Emerging Technologies, Microbiome, and Immunometabolism
2:30-4:35 p.m
Session Chair: To be announced
- Leveraging metabolic reprogramming to improve cellular therapies for cancer
Greg M. Delgoffe, University of Pittsburgh, Pittsburgh, Pennsylvania
Additional speakers to be announced
break
4:35-4:50 P.m.
Keynote Lecture
4:50-5:50 P.m.
- Ton Schumacher, Netherlands Cancer Institute, Amsterdam, Netherlands
Poster Session B
6-8:15 p.m
CONTINENTAL BREAKFAST
7-8 A.M.
Plenary Session 7: Myeloid and NK Cells
8-10:05 A.M.
Session Chair: To be announced
- Retroviral mimics costimulate TLR7/8/9 for enhanced activation of dendritic cells and myeloid cells to induce anti-tumor CD8+ T cells
Arthur M. Krieg, University of Massachusetts Chan Medical School, Needham, Massachusetts - Matthew Spitzer, University of California, San Francisco, California
Additional speaker to be announced
BREAK
10:05-10:20 A.M.
Plenary Session 8: Clinical and Biological Intersection
10:20 A.m.-12:45 p.m.
Session Chair: Fernando Vidal-Vanaclocha, The George Washington University, Washington, DC
- Integrating clinical and laboratory research to identify mechanisms of response and resistance to immune checkpoint therapy
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas - Fernando Vidal-Vanaclocha, The George Washington University, Washington, DC
Additional speaker to be announced